■这项真实世界的研究旨在调查galcanezumab对睡眠质量的影响,发作性偏头痛(EM)和慢性偏头痛(CM)患者的偏头痛结局和患者报告的多维结局指标(PROM)。
■54例发作性偏头痛(n=24)或慢性偏头痛(n=30)患者接受了3个月的一系列galcanezumab注射,并评估了睡眠质量。使用匹兹堡睡眠质量指数(PSQI)测量,以及偏头痛的结果,如每月头痛天数(MHD),每月偏头痛日(MMD),和头痛的严重程度。患者报告的结果指标(PROM),例如偏头痛残疾评估量表(MIDAS),头痛冲击试验-6(HIT-6),SF-36健康相关生活质量(HRQoL),贝克焦虑量表(BAI),和贝克抑郁量表(BDI)也被纳入评估。
■基线时睡眠质量差(PSQI总分≥5)的患者百分比为72.7%,在第1个月和第2个月分别降至57.5%和56.2%,分别。在注射galcanezumab的第三个月,在整个研究人群中,睡眠障碍领域观察到显著改善(p=0.016),以及基线时焦虑水平低(p=0.016)和无/轻度抑郁(p=0.035)的患者亚组。基线睡眠障碍患者在PSQI总分(p=0.027)和主观睡眠质量(p=0.034)和日间功能障碍(p=0.013)方面表现出明显改善。到第三个月。在1号,2nd,第三个月,MHD有显著改善(p<0.001),MMD(p<0.001),HIT-6评分(每个评分p<0.001),BAI评分(每个p<0.001),BDI评分(p范围从0.048到<0.001),和HRQoL评分(p范围从0.012到<0.001)。
■Galcanezumab在改善睡眠质量方面表现出显著的益处,以及对睡眠参数的基于合并症和特定领域的影响,这涉及基线时没有抑郁或焦虑的患者的睡眠障碍领域,但PSQI总分,基线睡眠障碍患者的主观睡眠质量和日间功能障碍.该治疗还促进偏头痛结局的快速发作增强以及各种PROM。
UNASSIGNED: This real-world study aimed to investigate the impact of
galcanezumab on sleep quality, migraine outcome and multidimensional patient-reported outcomes measures (PROMs) in patients with episodic migraine (EM) and chronic migraine (CM).
UNASSIGNED: Fifty-four patients with episodic migraine (n = 24) or chronic migraine (n = 30) received a 3-month series of
galcanezumab injections and were evaluated for sleep quality, measured using the Pittsburgh Sleep Quality Index (PSQI), as well as migraine outcomes such as monthly headache days (MHDs), monthly migraine days (MMDs), and headache severity. Patient-reported outcome measures (PROMs) such as the Migraine Disability Assessment Scale (MIDAS), Headache Impact Test-6 (HIT-6), SF-36 Health-related Quality of Life (HRQoL), Beck Anxiety Inventory (BAI), and Beck Depression Inventory (BDI) were additionally included in the assessment.
UNASSIGNED: The percentage of patients with poor sleep quality (total PSQI scores ≥ 5) was 72.7% at baseline, decreasing to 57.5% and 56.2% at the 1st and 2nd months, respectively. By the 3rd month of
galcanezumab injections, significant improvement was observed in the sleep disturbances domain in the overall study population (p = 0.016), and in subgroups of patients with low anxiety levels (p = 0.016) and none/minimal depression (p = 0.035) at baseline. Patients with sleep disorder at baseline exhibited marked improvements in total PSQI scores (p = 0.027) and in the subjective sleep quality (p = 0.034) and daytime dysfunction (p = 0.013) domains, by the 3rd month. Over the 1st, 2nd, and 3rd months, there were significant improvements in MHDs (p < 0.001), MMDs (p < 0.001), HIT-6 scores (p < 0.001 for each), BAI scores (p < 0.001 for each), BDI scores (p ranged from 0.048 to <0.001), and HRQoL scores (p ranged from 0.012 to <0.001).
UNASSIGNED: Galcanezumab demonstrates notable benefits in improving sleep quality, along with a comorbidity-based and domain-specific effect on sleep parameters, which involved sleep disturbances domain in patients without depression or anxiety at baseline but the total PSQI scores, subjective sleep quality and daytime dysfunction in those with sleep disorder at baseline. The treatment also facilitates rapid-onset enhancements in migraine outcomes as well as various PROMs.